{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:37Z","timestamp":1788491737589,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40744-022-00465-6","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T03:33:01Z","timestamp":1654227181000},"page":"1109-1118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Roxanne C. S.","family":"van Adrichem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke J. E.","family":"Voorneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeke J.","family":"Waverijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radjesh J.","family":"Bisoendial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/330662a0","volume":"330","author":"KJ Tracey","year":"1987","unstructured":"Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662\u20134.","journal-title":"Nature"},{"key":"465_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105\u201310.","journal-title":"Lancet"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s12325-019-00979-6","volume":"36","author":"R Markus","year":"2019","unstructured":"Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, Fanjiang G. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36:1833\u201350.","journal-title":"Adv Ther"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/rheumatology\/keh205","volume":"43","author":"J Braun","year":"2004","unstructured":"Braun J, Sieper J. Biological therapies in the spondyloarthritides\u2013the current state. Rheumatology (Oxford). 2004;43:1072\u201384.","journal-title":"Rheumatology (Oxford)"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2133.2004.06105.x","volume":"151","author":"AL Chew","year":"2004","unstructured":"Chew AL, Bennett A, Smith CH, Barker J, Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol. 2004;151:492\u20136.","journal-title":"Br J Dermatol"},{"issue":"237\u201355","key":"465_CR7","first-page":"v","volume":"30","author":"JJ Cush","year":"2004","unstructured":"Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004;30(237\u201355):v.","journal-title":"Rheum Dis Clin North Am"},{"key":"465_CR8","doi-asserted-by":"crossref","unstructured":"Mease PJ and Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis. 2005;64 Suppl 2:ii78\u201382.","DOI":"10.1136\/ard.2004.034157"},{"key":"465_CR9","doi-asserted-by":"crossref","unstructured":"Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis. 2002;61 Suppl 2:ii70\u20133.","DOI":"10.1136\/ard.61.suppl_2.ii70"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22\u201331.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"465_CR12","unstructured":"Schreiber S, Luger T, Mittendorf T, Mrowietz U, Muller-Ladner U, Schroder J, Stallmach A and Bokemeyer B. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]"},{"key":"465_CR13","doi-asserted-by":"crossref","unstructured":"Evolution der Biologika in der Entzundungsmedizin--Biosimilars in Gastroenterologie, Rheumatologie und Dermatologie. Dtsch Med Wochenschr. 2014;139:2399\u2013404.","DOI":"10.1055\/s-0034-1387371"},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","volume":"19","author":"R Moots","year":"2017","unstructured":"Moots R, Azevedo V, Coindreau JL, Dorner T, Mahgoub E, Mysler E, Scheinberg M, Marshall L. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37.","journal-title":"Curr Rheumatol Rep"},{"key":"465_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","volume":"6","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-world evidence on etanercept biosimilar SB4 in etanercept-naive or switching patients: a systematic review. Rheumatol Ther. 2019;6:317\u201338.","journal-title":"Rheumatol Ther."},{"key":"465_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH, Smolen JS. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58\u201364.","journal-title":"Ann Rheum Dis"},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679\u201387.","journal-title":"Ann Rheum Dis"},{"key":"465_CR18","first-page":"914","volume":"77","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, Assudani D. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914\u201321.","journal-title":"Ann Rheum Dis"},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24:1963\u20137.","journal-title":"Drug Discov Today"},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51\u20137.","journal-title":"Ann Rheum Dis"},{"key":"465_CR21","doi-asserted-by":"crossref","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Stasiuk B, Hilt J, Mosterova Z, Cheong SY and Ghil J. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017.","DOI":"10.1136\/annrheumdis-2017-211591"},{"key":"465_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"465_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214994","volume":"79","author":"J Kay","year":"2020","unstructured":"Kay J, Dorner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and \u201creal-world\u201d data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020;79: e44.","journal-title":"Ann Rheum Dis"},{"key":"465_CR24","doi-asserted-by":"crossref","unstructured":"Layegh Z, Ruwaard J, Hebing RCF, MJ LA, van der Weele W, Nurmohamed MT, Krieckaert C and Wolbink G. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. Int J Rheum Dis. 2019;22:869\u2013873.","DOI":"10.1111\/1756-185X.13512"},{"key":"465_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.","journal-title":"Arthritis Res Ther"},{"key":"465_CR26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Baek I, Ghil J. Switching from reference adalimumab to SB5 (Adalimumab Biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70:832\u201340.","journal-title":"Arthritis Rheumatol"},{"key":"465_CR27","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Urena S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Muller-Ladner U. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613\u201320.","journal-title":"Ann Rheum Dis"},{"key":"465_CR28","doi-asserted-by":"crossref","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG and Huys I. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther. 2020.","DOI":"10.1002\/cpt.1836"},{"key":"465_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104467","volume":"149","author":"FC Araujo","year":"2019","unstructured":"Araujo FC, Goncalves J, Fonseca JE. Biosimilars in rheumatology. Pharmacol Res. 2019;149: 104467.","journal-title":"Pharmacol Res"},{"key":"465_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102404","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Marotto D, Caporali R, Galeazzi M, Atzeni F, Hamar A, Soos B, Szekanecz Z. Biosimilars vs originators: Are they the same? Autoimmun Rev. 2019;18: 102404.","journal-title":"Autoimmun Rev"},{"key":"465_CR31","doi-asserted-by":"crossref","unstructured":"Schulze-Koops H and Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56:iv30-iv48.","DOI":"10.1093\/rheumatology\/kex277"},{"key":"465_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214374","volume":"79","author":"V Germain","year":"2020","unstructured":"Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, Federation H-U. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis. 2020;79: e11.","journal-title":"Ann Rheum Dis"},{"key":"465_CR33","doi-asserted-by":"crossref","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD and Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol. 2018;14:727\u2013740.","DOI":"10.1038\/s41584-018-0110-9"},{"key":"465_CR34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","volume":"35","author":"S Numan","year":"2018","unstructured":"Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35:1295\u2013332.","journal-title":"Adv Ther"},{"key":"465_CR35","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/apt.14509","volume":"47","author":"AA van Bodegraven","year":"2018","unstructured":"van Bodegraven AA, Boone NW. Editorial: nocebo effect and switching to biosimilars. Aliment Pharmacol Ther. 2018;47:850\u20131.","journal-title":"Aliment Pharmacol Ther"},{"key":"465_CR36","doi-asserted-by":"crossref","unstructured":"Elm v. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"465_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001016","volume":"5","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Ibsen R, Bilbo REQ, Lund Hetland M, Kjellberg J. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019;5: e001016.","journal-title":"RMD Open"},{"key":"465_CR38","doi-asserted-by":"crossref","unstructured":"Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sorensen IJ, Andersen LS, Grydehoj J, Mehnert F, Krogh NS and Hetland ML. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78:192\u2013200.","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"465_CR39","doi-asserted-by":"crossref","unstructured":"Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehoj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sorensen MV, Andersen LS, Gron KL, Krogh NS, Pedersen L, Hetland ML and all departments of rheumatology in D. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426\u20131431.","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"465_CR40","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, van den Ende CH, den Broeder AA. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol. 2018;70:1408\u201318.","journal-title":"Arthritis Rheumatol"},{"key":"465_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382:554\u201361.","journal-title":"N Engl J Med"},{"key":"465_CR42","doi-asserted-by":"crossref","unstructured":"Kravvariti E, Kitas GD and Sfikakis PP. The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice. Mediterr J Rheumatol. 2019;30:63\u201368.","DOI":"10.31138\/mjr.30.1.63"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00465-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00465-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00465-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T07:29:57Z","timestamp":1658734197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00465-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00465-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Roxanne C.S. van Adrichem, Geeke J. Waverijn and Radjesh J. Bisoendial designed the research, analyzed data and wrote the paper. Hanneke J.E. Voorneveld and Marc R. Kok wrote the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Roxanne C.S. van Adrichem, Hanneke J.E. Voorneveld, Geeke J. Waverijn, Marc R. Kok, and Radjesh J. Bisoendial have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All eligible patients,\u00a0when admitted to our outpatient clinic, agreed that their\u00a0clinical and laboratory data may be used for clinical practice\u00a0analysis to improve care\u00a0in an anonymous manner\u00a0(opt-out procedure). Therefore,\u00a0this\u00a0study has been granted an exemption from requiring ethics approval.\u00a0Personal data were handled in compliance with the Dutch Personal Data Protection Act and the privacy regulations of the Maasstad Hospital. This study was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}